SynthesisAnnals of surgical oncology2022
The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis.
Synthesis in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2024Pooled it
- Repeat cytoreductive surgery with HIPEC for colorectal peritoneal metastases: a systematic review.World journal of surgical oncology · 2024Pooled it
- A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Neoadjuvant Chemotherapy Prior to CRS/HIPEC for Metachronous Colorectal Peritoneal Metastases: No Survival Gain and Increased Perioperative Risk.Annals of surgical oncology · 2026Article
- Preoperative chemotherapy in colorectal peritoneal metastatic disease - a real-world observational cohort study.Pleura and peritoneum · 2026Article
- Optimal duration of neoadjuvant chemotherapy prior to CRS ± HIPEC for colorectal cancer: An assessment of survival and postoperative outcomes.Surgical oncology insight · 2026Article
- Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for children and young adults: experience from two high volume centers.Pleura and peritoneum · 2025Article
- Editorial: Highlighting Repeat Diagnostic Laparoscopy After Chemotherapy in Initially Unresectable Colorectal and Appendiceal Peritoneal Metastases.Annals of surgical oncology · 2025Article
- Current Status of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer (CRC).South Asian journal of cancer · 2024Review
- Neoadjuvant chemotherapy does not improve survival for patients with high volume colorectal peritoneal metastases undergoing cytoreductive surgery.World journal of surgical oncology · 2024Article
- Circulating Tumor DNA (ctDNA) Clearance May Predict Treatment Response in Neoadjuvant Colorectal Cancer Management.Journal of clinical medicine · 2024Article
- Peritoneal Metastasis: A Dilemma and Challenge in the Treatment of Metastatic Colorectal Cancer.Cancers · 2023Review
- ASO Author Reflections: Neoadjuvant Systemic Chemotherapy in Isolated Resectable Colorectal Peritoneal Metastases: Ready for Standard of Care?Annals of surgical oncology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is a well-recognised treatment option for the management of colorectal peritoneal metastases (CRPM). However, incorporating the routine use of neoadjuvant chemotherapy (NAC) into this management plan is controversial.
methodsA systematic review and meta-analysis were conducted to evaluate the impact of neoadjuvant chemotherapy on perioperative morbidity and mortality, and long-term survival of patients with CRPM undergoing CRS and HIPEC.
resultsTwelve studies met the inclusion criteria (n = 2,463 patients). Ten were retrospective cohort, one was prospective cohort, and one was a prospective randomised by design. Patients who received NAC followed by CRS and HIPEC experienced no difference in major perioperative morbidity and mortality compared with patients who underwent surgery first (SF). There was no difference in overall survival at 3 years, but at 5 years NAC patients had superior survival (relative risk [RR] 1.31; 95% confidence interval [CI] 1.11-1.54, P < 0.001). There were no differences in 1- and 3-year, disease-free survival (DFS) between groups. Study heterogeneity was generally high across all outcome measures.
conclusionsPatients who received neoadjuvant chemotherapy did not experience any increase in perioperative morbidity or mortality. The potential improvement in 5-year overall survival in patients receiving NAC is based on limited confidence due to several limitations in the data, but not sufficiently enough to curtail its use. The practice of NAC in this setting will remain heterogeneous and guided by retrospective evidence until prospective, randomised data are reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.